Erasca, Inc.

Erasca did not report revenue or EPS on this R&D update call. It said quarter-end cash was $322 million, before the $45 million oversubscribed equity financing, and that the financing extends cash runway from the first half of 2026 to the second half of 2026. For Naporafenib plus trametinib, management cited pooled Phase 1/2 data showing approximately 5 months median PFS versus 1.5 months for chemotherapy and about 2.8 months for single-agent MEK inhibitor, and median OS of about 13 to 14 months. Management said it is aligned with US and European health authorities on using PFS for potential initial approval and expects to initiate SEACRAFT-2 in the first half of 2024, with Stage 1 randomized readout in 2025.

Jonathan Lim framed the company as a precision oncology business focused on shutting down the RAS/MAPK pathway and said the Naporafenib program is the lead clinical asset. His tone was confident and data-driven, stressing that the mature OS analysis strengthens the case for the planned Phase 3 trial and that the program has already earned Fast Track designation. He also said the two-stage SEACRAFT-2 design and mandatory rash prophylaxis are intended to improve the benefit-risk profile and align with regulatory expectations.

David Chacko’s key financial update was the $45 million oversubscribed private placement, which, combined with the $322 million of cash at quarter-end, moved runway guidance out to the second half of 2026 from the first half of 2026. He described the financing as being with high-quality investors. No further margin, cash flow, or capital allocation metrics were discussed on the call.

Analysts focused on SEACRAFT-2 design choices, including whether PFS or OS had hierarchy, and management said there is no hierarchy and the trial can win on either endpoint, with regulatory alignment in the US and Europe. Questions also centered on dose selection, rash prophylaxis, and why the comparator arm includes physician’s choice of chemo versus single-agent MEK inhibitor; management said this reflects regional practice differences and that the Stage 1 dose-optimization readout will help pick the best regimen. On power, management said Stage 2 is largely powered around 80% for OS and 99% for PFS, with 350 patients total, and that they may revisit sample size depending on Stage 1 effect size.